Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29180108 | 0.90 | TSHR (0.59) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL5075045 | 0.80 | TSHR (0.67) | TSHRMAPK1LMNAHPGDL3MBTL1 | |
| SCHEMBL28546386 | 0.78 | SLC6A4 (0.50) | TSHRNOS1MAOASLC6A4 | |
| SCHEMBL10621289 | 0.78 | CHRNA7 (0.38) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL10338764 | 0.72 | CHRNA7 (0.35) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL28518525 | 0.72 | CHRNA7 (0.35) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL22655978 | 0.71 | NR1H2 (0.48) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL2279013 | 0.71 | MCL1 (0.53) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL8779780 | 0.71 | NR1H2 (0.41) | TSHRMAPK1NR1H2CYP3A4CHRNA7 | |
| SCHEMBL10597417 | 0.69 | TSHR (0.53) | TSHRMAPK1HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1604964-B1 | ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL | SEKISUI CHEMICAL CO LTD (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-7361776-B2 | Zero-valent transition metal complex and method for producing an organometallic compound using the same as a starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1604964-A1 | ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL | SEKISUI CHEMICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | OSTC, PORCN, SQLE | TSHR 4126/4885MAPK1 3667/4885NR1H2 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.